Visual radioembolism microsphere as well as preparation method and application thereof

By using radio-embolic microspheres with specific core-shell structures to load 90YF3 and barium sulfate, the existing radio-embolic microspheres have poor suspension ability in normal saline and blood and limited large vascular embolization ability are solved, and high-precision tumor treatment is achieved and postoperative evaluation.

CN119015452APending Publication Date: 2024-11-26CARDIOLINK SCI (SHENZHEN) MEDICAL TECH DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411142108.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing radio microspheres cannot be effectively suspended in normal saline and blood, resulting in poor delivery accuracy and feasibility. The large-size microspheres have limited embolization ability in larger blood vessels inside the tumor, high risk of mistuning, and lack of routine testing. Visualization ability under means.

Method used

Visual radio-embolic microspheres using shell structures formed by crosslinking N-hydroxyalkylacrylamide compounds with glycol glycidyl ether compounds and core structures formed by polymerization segments of ionic monomers, loading 90YF3 and barium sulfate , has a super hydrophilic core-shell structure, ensuring stable particle size and density of microspheres before and after loading, improving suspension capacity and delivery accuracy.

Benefits of technology

It has achieved stable suspension in normal saline and blood, reduced the risk of mistuning, improved the embolization effect of tumor large blood vessels, and has the ability to visualize under X-ray, which has enhanced delivery accuracy and postoperative evaluation of surgical results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015452A_ABST
    Figure CN119015452A_ABST
Patent Text Reader

Abstract

The invention relates to a visual radioembolism microsphere as well as a preparation method and application thereof, and belongs to the technical field of radiomicrospheres. The visual radioembolism microsphere comprises 90YF3, barium sulfate and an embolism microsphere, wherein the 90YF3 and the barium sulfate are loaded inside the embolism microsphere. Wherein the embolization microsphere has a shell structure formed by cross-linking an N-hydroxyalkyl acrylamide compound and an ethylene glycol glycidyl ether compound, and a core structure formed by an ionic monomer polymerization chain segment. The embolism microsphere with a specific structure and composition is not obviously reduced in performance before and after loading, has a visualization capability under X rays, keeps a large particle size, a small density, low hardness and high elasticity, can improve delivery accuracy and feasibility, is beneficial to postoperative evaluation of an operation effect, can improve an embolism effect of tumor large vessels, and has a good application prospect. And the blood vessel is not easily damaged in the delivery process. In addition, the core-shell structure enables heavy metal ions not to leak easily, and the safety risk is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of radioactive microspheres, and in particular to a visualized radioembolization microsphere and a preparation method and application thereof. Background Art

[0002] Radiotherapy is one of the important means of cancer treatment. Radiotherapy combined with chemotherapy, surgery and embolization therapy has achieved good clinical therapeutic effects and saved and prolonged the lives of countless patients. In the past, radiotherapy had to penetrate the surface of the skin, tissues and organs. While killing tumor cells, it was inevitable to cause serious damage to normal tissues and organs. Although the injection of nuclear radiopharmaceuticals has good tumor targeting, it is inevitable that there will be off-target situations, and the side effects of systemic radiation are large. 125 I-particle implantation requires implanting metal particles through organ puncture, which is risky. The newly developed radioactive microsphere SIRT therapy uses a microcatheter to deliver microspheres with radionuclides directly into the target blood vessels of the tumor, accurately killing tumor cells at the tumor site, thereby achieving the effect of treating the tumor.

[0003] The radioactive microspheres currently on the market include glass microspheres, resin microspheres and carbon microspheres. All three types of microspheres are loaded with radioactive elements. 90 Y, by 90 Y undergoes β decay to produce high-energy rays to kill tumor cells, causing irreversible damage to tumor tissue and leading to tumor necrosis. The density of the glass microspheres is 3.6g / cm 3 The density of resin microspheres and carbon microspheres are 1.6 g / cm 3 and 1.8 g / cm 3 , which are much larger than the density of aqueous solution or saline solution, and cannot be effectively suspended in saline solution and blood, making it difficult to deliver into tumor target blood vessels through microcatheters, affecting the accuracy and feasibility of delivery. Moreover, a larger density is usually accompanied by a greater hardness and poorer elasticity, which can easily damage the blood vessel wall during delivery. Therefore, existing radioactive microspheres can only use smaller particle sizes (<70μm), and have limited embolization capabilities for larger blood vessels inside tumors. In addition, since small-particle microspheres have the possibility of leaking out from the ends of tumor microvessels (for example, clinical studies have shown that liver microvessels are approximately 30μm), there is a greater risk of accidental embolization.

[0004] In addition, most of the above radioactive microspheres do not have the visualization ability under conventional detection methods (DSA, CT and MRI), which seriously affects the delivery accuracy and is not conducive to the postoperative evaluation of surgical effects. International patent application WO2020 / 237399A1 discloses adding barium oxide and tantalum oxide with strong X-ray absorption ability to glass microspheres, so that 90Y glass radioactive microspheres have the ability to be visualized under X-ray detection equipment, which increases the controllability of the embolization process, but the addition of heavy metal oxides further increases the density of the glass microspheres, which cannot meet the requirements of clinical use. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present application provides a visualized radioembolization microsphere and a preparation method and application thereof.

[0006] In a first aspect, the present invention provides a visualized radioembolization microsphere, comprising 90 YF3, barium sulfate and embolic microspheres, 90 YF3 and barium sulfate are loaded inside the embolic microspheres, wherein the embolic microspheres have a shell structure formed by cross-linking N-hydroxyalkyl acrylamide compounds and ethylene glycol glycidyl ether compounds, and a core structure formed by ionic monomer polymerized chain segments.

[0007] The embolic microspheres used in this application have a super-hydrophilic core-shell structure, the shell layer is a relatively dense structure formed by the polymerization of a large number of polyethylene glycol derivative monomers, and the core layer is a relatively loose structure formed by the polymerization of ionic monomers. The dense and highly hydrophilic polyethylene glycol derivative structure of the outer layer makes the microspheres have strong toughness, and the specific core-shell structure makes the embolic microspheres have a large particle size, high elasticity, high toughness and low density. Before and after loading, the dense shell structure does not significantly shrink the particle size of the embolic microspheres, and the loose core layer structure does not significantly increase the density after loading. Therefore, the obtained visualized radioembolic microspheres can maintain a large particle size while having a small density, good suspension ability, and can improve the embolic effect of large tumor blood vessels. And the visualized radioembolic microspheres also have lower hardness and higher elasticity, and are not easy to damage blood vessels during delivery. In addition, the dense shell structure also makes it difficult for heavy metal ions to leak, reducing safety risks.

[0008] In some embodiments of the present application, the glycol glycidyl ether compound is selected from at least one of ethylene glycol diglycidyl ether, diethylene glycol diglycidyl ether, triethylene glycol diglycidyl ether, tetraethylene glycol diglycidyl ether, PEG200 diglycidyl ether or PEG500 diglycidyl ether. The N-hydroxyalkyl acrylamide compound is selected from at least one of N-hydroxymethyl acrylamide, N-hydroxyethyl acrylamide, N-[tris(hydroxymethyl)methyl] acrylamide, N-(2-hydroxypropyl) acrylamide, N-(hydroxymethyl) methacrylamide, N-(hydroxyethyl) methacrylamide, N-[tris(hydroxymethyl)methyl] methacrylamide or N-(2-hydroxypropyl) methacrylamide. The ionic monomer is selected from at least one of sodium acrylate, sodium methacrylate, sodium p-styrene sulfonate or sodium vinyl sulfonate.

[0009] In some embodiments of the present application, the particle size of the visualized radioembolization microspheres is 100-500 μm.

[0010] Compared with the radioactive microspheres in the prior art, the visualized radioembolization microspheres provided in the present application have a larger particle size (>70 μm), and thus can be effectively used for embolization of larger blood vessels inside tumors, reducing the risk of accidental embolization.

[0011] In some embodiments of the present application, the suspension time of the visualized radioembolization microspheres in physiological saline is greater than 5 minutes.

[0012] In some embodiments of the present application, the density of the visualized radioembolization microspheres is less than 1.25 g / cm 3 .

[0013] The density of the visualized radioembolization microspheres provided in the present application is relatively close to that of saline and blood, and they can be stably suspended in saline and blood for a long time, so they can be easily delivered into tumor target vessels through a microcatheter, thereby improving the accuracy and feasibility of delivery.

[0014] In some embodiments of the present application, the method for preparing embolic microspheres comprises the following steps:

[0015] Prepare the aqueous phase: cross-link the ethylene glycol glycidyl ether compound and the aqueous solution of the N-hydroxyalkyl acrylamide compound, and then add the ionic monomer and the initiator after the cross-linking to prepare the aqueous phase;

[0016] Preparing the oil phase: mixing the oil-soluble dispersant and the oil-soluble solvent to form the oil phase;

[0017] Inverse suspension polymerization reaction: Under certain temperature and stirring conditions, slowly add water phase into the oil phase to form an oil-in-water inverse suspension polymerization system, add a certain amount of catalyst into the reaction system, heat it to the predetermined reaction temperature, and when the reaction is completed, embolic microspheres with a core-shell structure are obtained.

[0018] In a second aspect, the present application provides a method for preparing the above-mentioned visualized radioembolization microspheres, comprising the following steps:

[0019] The embolic microspheres are loaded with barium sulfate through the first ion exchange to obtain visualized embolic microspheres;

[0020] The visualized embolic microspheres were loaded with a second ion exchange 90 YF3, obtain visualized radioembolization microspheres.

[0021] Conventional microspheres loaded with radionuclides are used in the prior art 90After Y and barium sulfate are added, not only the particle size will be reduced, but the density and corresponding strength will also increase significantly, so it cannot meet the clinical application requirements. In this application, embolic microspheres with a specific core-shell structure and structural composition are used. The core structure is an anion skeleton and free cations (such as sodium ions), so that two ion exchanges can be used to stably load radionuclides. 90 Y and barium sulfate, the preparation method is simple, and the performance of the embolic microspheres does not decrease significantly before and after loading.

[0022] In some embodiments of the present application, the first ion exchange step comprises:

[0023] After the embolic microspheres are dehydrated and dried, they are mixed with a soluble barium salt aqueous solution, stirred, and allowed to stand. After the embolic microspheres are precipitated, the upper liquid is removed to obtain the loaded Ba 2+ of microspheres;

[0024] To load Ba 2+ A soluble sulfate aqueous solution is added to the microspheres, and after stirring and precipitation, the visualized embolization microspheres loaded with barium sulfate are obtained.

[0025] In some embodiments of the present application, the second ion exchange step includes:

[0026] After the visualized embolization microspheres are dehydrated and dried, they are mixed with a soluble yttrium salt aqueous solution, stirred, and allowed to stand. After the visualized embolization microspheres are precipitated, the upper liquid is removed to obtain the loading 90 Y 3+ Visualization of embolic microspheres;

[0027] To load 90 Y 3+ The visualized embolization microspheres were added with a saturated soluble fluoride salt solution, stirred and precipitated to obtain the loaded 90 Visualization of YF3 radioembolization microspheres.

[0028] In a third aspect, an embodiment of the present application further provides a use of the above-mentioned visualized radioembolization microspheres in the preparation of a drug for treating solid malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 This is a photo of the embolic microspheres mixed with the BaCl2 aqueous solution in Example 1;

[0031] Figure 2 is an optical micrograph of the mixture of the embolic microspheres and the BaCl2 aqueous solution in Example 1;

[0032] Figure 3 This is a photo of the embolic microspheres mixed with the Na2SO4 aqueous solution in Example 1;

[0033] Figure 4 This is an optical micrograph of the embolic microspheres mixed with the Na2SO4 aqueous solution in Example 1;

[0034] Figure 5 is an optical micrograph of the visualized radioembolization microspheres prepared in Example 1;

[0035] Figure 6 A in the figure is the in vitro micro-CT visualization test image of the embolic microspheres in Example 1; Figure 6 B is an in vitro micro-CT visualization test image of the visualized embolic microspheres in Example 1; Figure 6 C in FIG. 1 is an in vitro micro-CT visualization test image of the visualized radioembolization microspheres in Example 1. DETAILED DESCRIPTION

[0036] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0037] The following is a detailed description of a visualized radioembolization microsphere and a preparation method thereof according to an embodiment of the present application.

[0038] The present application embodiment provides a visualized radioembolization microsphere, comprising 90 YF3, barium sulfate and embolic microspheres, 90 YF3 and barium sulfate are loaded inside the embolic microspheres, wherein the embolic microspheres have a shell structure formed by cross-linking N-hydroxyalkyl acrylamide compounds and ethylene glycol glycidyl ether compounds, and a core structure formed by ionic monomer polymerized chain segments.

[0039] The embolic microspheres provided in the present application have a super-hydrophilic core-shell structure. The shell layer is a relatively dense structure formed by the polymerization of a large number of polyethylene glycol derivative monomers, and the core layer is a relatively loose structure formed by the polymerization of ionic monomers. The dense and highly hydrophilic polyethylene glycol derivative structure of the outer layer makes the microspheres have high elasticity, high toughness and low density. 90There was no significant decrease in the performance of the embolic microspheres before and after YF3 and barium sulfate. The visualized radioembolic microspheres have the ability to be visualized under X-rays, which improves the accuracy and feasibility of delivery, and is conducive to the evaluation of surgical effects after surgery. Moreover, due to their large particle size and small density, they have good suspension ability and can improve the embolization effect of large tumor blood vessels. The visualized radioembolic microspheres also have low hardness and high elasticity, and are not easy to damage blood vessels during delivery. In addition, because the embolic microspheres used have a core-shell structure, heavy metal ions are not easy to leak, reducing safety risks.

[0040] The particle size of the visualized radioembolic microspheres of the present application can be 90-500 μm, and correspondingly, the particle size of the corresponding embolic microspheres before loading is 100-500 μm. As an example, when the particle size of the embolic microspheres is 100-200 μm, the particle size of the corresponding visualized radioembolic microspheres after loading is 93-187 μm; when the particle size of the embolic microspheres is 300-400 μm, the particle size of the corresponding visualized radioembolic microspheres after loading is 283-369 μm. In other words, the particle size of the embolic microspheres in the present application will not change significantly after microscopic modification and radiomodification loading, that is, a larger particle size range can still be maintained, and the minimum particle size value is also greater than the 70 μm commonly used in the prior art.

[0041] The suspension time in saline is greater than 5 minutes, and the density can be as low as 1.23 g / cm 3 Correspondingly, the density of the corresponding embolic microspheres before loading is only about 1 g / cm 3 , the suspension time in physiological saline can be greater than 10 min. As an example, the density of the corresponding embolic microspheres before loading is 1.06 g / cm 3 The density of the corresponding visualized radioembolization microspheres after loading was only 1.23 g / cm 3 The suspension time in physiological saline is about 8 minutes. That is to say, after micro-modification and radiation modification loading, the density of the embolic microspheres in the present application is only slightly increased, but it is much lower than the resin microspheres in the prior art (1.6 g / cm 3 ).

[0042] In addition, the visualized radioembolization microspheres of the present application also have higher elasticity and lower hardness. For example, the strength measured by a texture analyzer may be lower than 150 g, and the elasticity is no higher than 65%. The strength and elasticity of the embolization microspheres do not decrease significantly before and after loading.

[0043] Accordingly, the present application also provides a method for preparing the above-mentioned visualized radioembolization microspheres, comprising the following steps:

[0044] (1) Preparing embolic microspheres, comprising the following steps:

[0045] S11: preparing the aqueous phase: cross-linking the aqueous solution of the ethylene glycol glycidyl ether compound and the N-hydroxyalkyl acrylamide compound, and then adding the ionic monomer and the initiator after the cross-linking to prepare the aqueous phase.

[0046] The ethylene glycol diglycidyl ether compound may be at least one of ethylene glycol diglycidyl ether, diethylene glycol diglycidyl ether, triethylene glycol diglycidyl ether, tetraethylene glycol diglycidyl ether, PEG200 diglycidyl ether or PEG500 diglycidyl ether.

[0047] The N-hydroxyalkyl acrylamide compound can be at least one of N-hydroxymethyl acrylamide, N-hydroxyethyl acrylamide, N-[tris(hydroxymethyl)methyl]acrylamide, N-(2-hydroxypropyl)acrylamide, N-(hydroxymethyl)methacrylamide, N-(hydroxyethyl)methacrylamide, N-[tris(hydroxymethyl)methyl]methacrylamide or N-(2-hydroxypropyl)methacrylamide.

[0048] The ionic monomer may be at least one of sodium acrylate, sodium methacrylate, sodium p-styrene sulfonate or sodium vinyl sulfonate.

[0049] The initiator may be at least one of ammonium persulfate, sodium persulfate and potassium persulfate.

[0050] The cross-linking reaction is carried out in the presence of an alkaline substance, for example, in an aqueous solution of sodium hydroxide or potassium hydroxide. The reaction can be carried out at room temperature, and the reaction time can be 1-6 hours, for example, 1 hour, 2 hours, 5 hours, etc.

[0051] S12 prepares the oil phase: the oil-soluble dispersant and the oil-soluble solvent are mixed to form the oil phase.

[0052] The oil-soluble dispersant may be cellulose acetate butyrate, and the oil-soluble solvent may be at least one of butyl acetate, ethyl acetate, methyl acetate or propyl acetate.

[0053] S13 reverse suspension polymerization reaction: under certain temperature and stirring conditions, slowly add water phase into the oil phase to form an oil-in-water reverse suspension polymerization system, add a certain amount of catalyst into the reaction system, heat the reaction system to a predetermined temperature, stop stirring and cool after the reaction is completed, let it stand until the reaction system is stratified, separate the oil phase, collect the microspheres and repeatedly wash and purify and screen, and react for a period of time to obtain embolic microspheres with a core-shell structure.

[0054] The catalyst may be at least one of tetramethylethylenediamine and triethylamine. As an example, in the reverse suspension polymerization reaction, the reverse suspension polymerization system may be reacted at 50°C for 30 minutes, and then after adding the catalyst, the temperature is raised to a predetermined temperature such as 80°C for 4 hours.

[0055] During the preparation process, firstly, ethylene glycol glycidyl ether compounds and aqueous solutions of N-hydroxyalkyl acrylamide compounds are cross-linked to obtain a neutral molecular shell of polyethylene glycol derivatives modified with terminal acrylamide. When reverse suspension polymerization is then carried out with ionic monomers, the ionic monomers with ionic functional groups tend to be distributed inside the liquid to form an inner core, thereby obtaining embolic microspheres with anionic skeletons and free cations as the core and neutral molecules of polyethylene glycol derivatives modified with terminal acrylamide as the shell.

[0056] Since the interior of the embolic microspheres is a core structure of ionic monomer polymer segments, that is, the core structure has an anion skeleton and free cations, the ion exchange method can be simply used for imaging modification and radiation modification.

[0057] (2) Preparation of visualized embolic microspheres: The embolic microspheres are loaded with barium sulfate through the first ion exchange to obtain visualized embolic microspheres.

[0058] Since the embolic microspheres are composed of neutral molecules as the shell, anionic skeletons and free cations (such as sodium ions) as the core, Ba 2+ Can diffuse into the core layer to replace the free cations, and then Ba 2+ The core layer of the precipitated loaded and embolic microspheres is formed with sulfate ions. The principle of the first ion exchange can be expressed by the following formula:

[0059]

[0060] The first ion exchange method may include: dehydrating and drying the embolic microspheres and mixing them with a soluble barium salt aqueous solution, stirring and standing, and removing the upper liquid after the embolic microspheres are precipitated to obtain a loaded Ba 2+ The microspheres were washed with purified water. 2+ microspheres to remove free Ba ​​on the surface 2+ . To load Ba 2+ A soluble sulfate aqueous solution is added to the microspheres, and after stirring and precipitation, the visualized embolization microspheres loaded with barium sulfate are obtained.

[0061] The soluble barium salt aqueous solution may be a barium chloride (BaCl2) aqueous solution, and the soluble sulfate salt aqueous solution may be a sodium sulfate (Na2SO4) aqueous solution. The mass concentration of the soluble barium salt aqueous solution may be 5-35%, for example, specifically 15%. The mass concentration of the soluble sulfate salt aqueous solution may be 5-50%, for example, specifically 35%.

[0062] (3) Preparation of visualized radioactive microspheres: The visualized embolic microspheres were loaded with ion exchange 90 YF3, to obtain visualized radioembolization microspheres. The principle of the second ion exchange can be expressed by the following formula:

[0063]

[0064] The principle is the same as the first ion exchange. 3+ It can diffuse into the core layer of the visualized embolic microspheres, produce ion exchange with the cations after the first ion exchange, and then the fluoride ions and Y 3+ The yttrium fluoride precipitate is combined and loaded on the core layer.

[0065] The second ion exchange step may include: drying and mixing the visualized embolization microspheres with a soluble yttrium salt aqueous solution, stirring, and standing, and removing the upper liquid after the visualized embolization microspheres are precipitated to obtain a loaded Y 3+ Visualization of embolic microspheres, wash the loaded Y 3+ Visualization of embolic microspheres, removal of free Y 3+ . To load Y 3+ The saturated soluble fluoride salt solution was added to the visualized embolization microspheres, and the loaded yttrium fluoride ( 90 YF3) Visualization of radioembolic microspheres.

[0066] As an example, the soluble yttrium salt aqueous solution can be yttrium sulfate ( 90 Y2(SO4)3) aqueous solution, the saturated soluble fluoride salt aqueous solution can be a saturated sodium fluoride (NaF) or potassium fluoride (KF) aqueous solution.

[0067] In the present application, a polyethylene glycol derivative modified with terminal acrylamide is polymerized with an ionic monomer to obtain an embolic microsphere with a core-shell structure. The embolic microsphere has a super-hydrophilic core-shell structure, and the core structure is an anionic skeleton and free cations (such as sodium ions), so that the radionuclide can be loaded simply by two ion exchanges. 90 Y and barium sulfate, the preparation method is simple, and the performance of the embolic microspheres does not decrease significantly before and after loading, that is, they can still maintain a larger particle size and a smaller density, as well as a larger elasticity and a lower hardness.

[0068] In addition, the present application also provides an application of a visualized radioembolization microsphere in the preparation of a drug for treating solid malignant tumors. Since the core layer of the visualized radioembolization microsphere is rich in ionic groups, the drug can enter the core from the outer shell and combine with the ionic groups, thereby achieving stable loading.

[0069] The features and performance of the present application are further described in detail below in conjunction with the embodiments.

[0070] Example 1

[0071] This embodiment provides a visualized radioembolization microsphere, which is prepared by the following method:

[0072] (1) Preparation of embolic microspheres

[0073] Prepare the aqueous phase: accurately weigh 3.2g of diethylene glycol diglycidyl ether into a wide-mouth bottle, add 6mL of 12% NaOH aqueous solution, place on a magnetic stirrer and stir at room temperature for 0.5h. Add 9.5mL of 50% mass fraction N-hydroxyethyl acrylamide aqueous solution into the bottle and continue stirring for 2h. Neutralize the system solution with concentrated hydrochloric acid to neutrality, add an aqueous solution containing 6.5g of sodium acrylate, stir for 0.5h, then add 180mg of ammonium persulfate, stir evenly for 0.5h and prepare the aqueous phase.

[0074] Prepare the oil phase: add 3 g of cellulose acetate butyrate into 100 mL of butyl acetate and stir to dissolve at 50°C to form a uniform oil phase system.

[0075] Reverse suspension polymerization: Slowly add the aqueous solution prepared above to the oil phase solution at 50°C and 300 rpm stirring to form an oil-in-water reverse suspension polymerization system. Keep the reaction at 50°C for 30 minutes, then add 1.2 mL of tetramethylethylenediamine (TMEDA) to the oil phase and heat to 80°C for 4 hours.

[0076] Purification: After the reaction is completed, the obtained microspheres are repeatedly washed 3-5 times with butyl acetate, purified water and 5% sodium bicarbonate aqueous solution to obtain polyethylene glycol-sodium polyacrylate (PEG-PAAS) embolic microspheres with a core-shell structure.

[0077] (2) Preparation of visualized embolic microspheres

[0078] 1 g of PEG-PAAS embolization microspheres were dehydrated and then added to 10 mL of 15% BaCl2 aqueous solution. After stirring for 1 h, the microspheres were allowed to settle (see Figure 1 and Figure 2 ), and the upper layer of liquid was aspirated. Then 10 mL of purified water was added and stirred and washed for 3 times, and the upper layer of liquid was aspirated after ultrasonication for 10 min. Then 10 mL of 349 mg of Na2SO4 aqueous solution was added, stirred for 10 min, and allowed to stand to allow the microspheres to precipitate, and visualized embolic microspheres were obtained (see Figure 3 and Figure 4 ).

[0079] (3) Preparation of visualized radioembolization microspheres

[0080] 1g of visualized embolization microspheres was dehydrated and dried, then added to 10mL of 30% yttrium sulfate aqueous solution, stirred for 1h, and then allowed to stand to allow the microspheres to precipitate, and the upper layer of liquid was aspirated. Then 10mL of purified water was added and stirred and washed for 3 times, and the upper layer of liquid was aspirated after ultrasonic treatment for 10min, and then saturated potassium fluoride solution was added, stirred for 30min, and allowed to stand to allow the microspheres to precipitate, to obtain visualized radioembolization microspheres (see Figure 5 ).

[0081] Example 2

[0082] (1) Preparation of embolic microspheres

[0083] Prepare the aqueous phase: accurately weigh 3g of ethylene glycol diglycidyl ether into a wide-mouth bottle, add 6mL of 15% NaOH aqueous solution, place on a magnetic stirrer and stir at room temperature for 0.5h. Add 9mL of 50% N-hydroxymethyl acrylamide aqueous solution into the bottle and continue stirring for 2h. Neutralize the system solution with concentrated hydrochloric acid to neutrality, add an aqueous solution containing 8.7g of sodium methacrylate, stir for 0.5h, then add 160mg of potassium persulfate, stir evenly for 0.5h and prepare the aqueous phase.

[0084] Prepare the oil phase: add 3 g of cellulose acetate butyrate into 100 mL of butyl acetate and stir to dissolve at 50°C to form a uniform oil phase system.

[0085] Reverse suspension polymerization: Slowly add the aqueous solution prepared above to the oil phase solution at 50°C and 300rpm stirring to form an oil-in-water reverse suspension polymerization system. Keep the reaction at 50°C for 30 minutes, then add 1.0mL of triethylamine (Et3N) to the oil phase and heat to 80°C for 4 hours.

[0086] Purification: After the reaction is completed, the obtained microspheres are washed repeatedly 3-5 times with butyl acetate, purified water and 5% sodium bicarbonate aqueous solution in turn to obtain polyethylene glycol-sodium polyacrylate hydrogel microspheres with a core-shell structure.

[0087] The preparation methods of visualized embolic microspheres and visualized radioembolic microspheres are the same as those in Example 1.

[0088] Comparative Example 1

[0089] (1) Preparation of embolic microspheres

[0090] Prepare the aqueous phase: add 100g of polyvinyl alcohol to 500mL of water, heat to 95°C, stir and dissolve to form a uniform solution; then add 3g of (N-(2,2-dimethoxy)-2-methylacrylamide, stir evenly, add 30mL of hydrochloric acid, and continue stirring and reacting at 25°C for 1h to obtain a polyvinyl alcohol aqueous solution. Stir 10g of sodium 2-acrylamide-2-methylpropane sulfonate, 0.3g of potassium persulfate, and 100g of polyvinyl alcohol aqueous solution evenly to a uniform solution to obtain the aqueous phase.

[0091] Prepare the oil phase: add 20 g of cellulose acetate butyrate into 500 mL of butyl acetate, stir and dissolve at 35° C. to form a uniform solution to obtain the oil phase.

[0092] Reverse suspension polymerization reaction: Under stirring conditions, slowly add the aqueous phase solution to the oil phase to form an oil-in-water reverse suspension polymerization system. After the addition is completed, continue to add a certain amount of catalyst tetramethylethylenediamine to the reaction system, and the reverse suspension polymerization reaction begins. After the reaction is completed, stop stirring and heating, let the reaction system stand to separate, separate the oil phase, collect the microspheres and wash them repeatedly to obtain modified polyvinyl alcohol microspheres with a core-shell structure.

[0093] The preparation methods of visualized embolic microspheres and visualized radioembolic microspheres are the same as those in Example 1.

[0094] Comparative Example 2

[0095] 3.3 g of acrylamide, 6.6 g of sodium 2-acrylamide-2-methylpropanesulfonate, 0.55 g of polyethylene glycol diacrylate, 0.22 g of potassium persulfate, and 0.33 g of tetramethylethylenediamine were weighed and mixed with 20 mL of water to form a mixed aqueous phase solution. The mixed aqueous phase solution was dropped into the oil phase solution under stirring, and the mass ratio of the mixed aqueous phase solution to the oil phase solution was 1:10. The mixture was reacted at 40° C. for 2 h to form a prepolymer intermediate.

[0096] Add 1 mCi of yttrium sulfate solution to the prepolymer intermediate dispersion, add tetramethylethylenediamine dropwise at 50°C, and react for 3 hours to obtain 90 Y core particles. Weigh 0.1 mg 90 Y core particles, 2 mg sodium alginate, 0.2 mg polyethylene glycol glycidyl ether, and 0.5 mg sodium hydroxide solution (concentration 5 wt%) were mixed, heated to 40°C, stirred for reaction for 2 h, allowed to stand for 30 min, filtered, and washed to obtain Y-90 microspheres.

[0097] Performance testing and result analysis

[0098] (1) Visualization capabilities

[0099] The visualization performance is reflected by in vitro micro-CT images and HU values. The HU value test method is as follows: the visualized embolic microspheres of each embodiment are subjected to Micro CT testing, and the linear opacity of the visualized embolic microsphere samples prepared according to the above method is evaluated. The beads are suspended in 0.5% agarose gel in a Nunc cryostat vial, and the linear opacity of the visualized embolic microspheres is tested using a micro-CT imaging system scanner equipped with a tungsten anode and micro-computed tomography (micro-CT imaging system). The image segmentation is then used to separate the polymer from the pore structure in order to report the polymer radiation density. The radiation density in HU is then calculated using a water standard obtained on the same day.

[0100] The HU values ​​of the embolic microspheres, visualized embolic microspheres and visualized radioembolic microspheres in the examples and comparative examples are shown in Table 1:

[0101] Table 1 HU values ​​of samples in the examples and comparative examples

[0102]

[0103] Figure 6 A, B, and C are respectively in vitro micro-CT visualization test images of the embolic microspheres, visualized embolic microspheres, and visualized radioembolic microspheres in Example 1. Figure 6 As shown in Table 1, the HU value of the samples loaded with yttrium fluoride and barium sulfate is higher, and has better visualization ability under X-ray. The HU value of each sample in Example 2 is equivalent to that in Example 1, while the HU value of the modified polyvinyl alcohol microspheres selected in Comparative Example 1 is lower than that of Examples 1 and 2.

[0104] In comparative example 2, only the load 90 Y does not carry a contrast agent (barium sulfate) and does not produce an image under the CT imaging system.

[0105] (2) Physical properties

[0106] The density, stable suspension time, strength and elasticity of each sample microsphere in the embodiment and the comparative example were tested respectively, and the test method was as follows:

[0107] Density: measured by density gradient column method.

[0108] Stable suspension time: Take 1 mL of microspheres, place them in a measuring cylinder, add 10 mL of normal saline, shake gently, and test the time it takes for the microspheres to precipitate to 70% of the total amount. This time is the time the microspheres can be suspended in normal saline.

[0109] Strength / elasticity: The microspheres are spread on a slide to form a single layer, and the strength and elasticity are measured using a texture analyzer (TA-XTplusC). Strength is defined as the maximum force during 50% compression, and elasticity is defined as whether the microspheres can recover their spherical shape after being compressed to a certain percentage.

[0110] The above test results are shown in Table 2:

[0111] Table 2 Physical properties of each sample in the embodiments and comparative examples

[0112]

[0113] As shown in Table 2, when the embolic microspheres used in Examples 1 and 2 are polyethylene glycol-sodium polyacrylate with a core-shell structure, they have lower density, lower strength and higher elasticity, and their original density is only about 1 g / cm 3 After two ion exchange loadings, the density, strength and elasticity of the visualized radioactive microspheres did not increase significantly, and the stable suspension time in physiological saline was greater than 5 min. In Comparative Example 1, when the embolic microspheres were modified polyvinyl alcohol microspheres without a core-shell structure, although their original density, strength and elasticity were low, after development modification and radiomodification, their performance was significantly reduced, with a density of up to 2.32 g / cm 3 The stable suspension time in physiological saline is less than 1 minute, the density is as high as 1.86, and it has high strength and poor elasticity, which cannot meet the needs of clinical applications.

[0114] In Comparative Example 2, a prepolymer intermediate is first formed, and then 90 Y is loaded through coordination polymerization, and finally secondary cross-linking polymerization makes 90 Y is stably loaded inside the microspheres. This method is used to complete the process of preparing microspheres. 90 Y load, only load 90 In the case of Y, its density is as high as 1.86g / cm 3 , and the strength and elasticity are worse than those of the simultaneous load in this application 90 Embolization microspheres of YF3 and barium sulfate.

[0115] (3) Particle size test

[0116] The embolic microspheres prepared in Example 1 were finely sieved through a sieve to obtain five specifications of 100-200 μm, 200-300 μm, 300-400 μm, and 400-500 μm (exceeding the limit ratio <5%), and the corresponding visualized radioactive microspheres were measured and statistically analyzed for particle size changes. (Method: After shaking well, a small amount of wet microspheres soaked in pure water were placed on a glass slide, and an optical microscope was used to measure the particle size of all microspheres in two fields of view and included in the statistics to obtain the particle size range. The results are shown in Table 3.

[0117] Table 3 Particle size of each sample in Example 1

[0118]

[0119] As can be seen from Table 3, the particle size of the embolic microspheres in the present application is almost unaffected after development modification and radiation modification, and can still be maintained at 90-500 μm, which is larger than 70 μm in the prior art. It can be used for embolization of larger blood vessels inside tumors to reduce the risk of misembolization.

[0120] In summary, in this application, embolic microspheres with a specific core-shell structure and composition are used to load 90 The visualized radioembolization microspheres obtained by YF3 and barium sulfate have no significant performance decrease before and after loading. While having the ability to be visualized under X-rays, they maintain a larger particle size, a smaller density, a lower hardness, and a higher elasticity, which can improve the delivery accuracy and feasibility, facilitate the evaluation of surgical effects after surgery, and can improve the embolization effect of large tumor blood vessels, and are not easy to damage blood vessels during delivery. In addition, the core-shell structure makes it difficult for heavy metal ions to leak, reducing safety risks. The visualized radioembolization microspheres can be effectively used in the preparation of drugs for the treatment of solid malignant tumors.

[0121] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present application.

Claims

1. A visualized radioembolization microsphere, characterized in that: include 90 YF3, barium sulfate and embolic microspheres, 90 YF3 and barium sulfate are loaded inside the embolic microspheres; The embolic microspheres have a shell structure formed by cross-linking N-hydroxyalkyl acrylamide compounds and ethylene glycol glycidyl ether compounds, and a core structure formed by ionic monomer polymerized chain segments.

2. The visualized radioembolization microsphere according to claim 1, characterized in that: The glycol glycidyl ether compound is selected from at least one of ethylene glycol diglycidyl ether, diethylene glycol diglycidyl ether, triethylene glycol diglycidyl ether, tetraethylene glycol diglycidyl ether, PEG200 diglycidyl ether or PEG500 diglycidyl ether; the N-hydroxyalkyl acrylamide compound is selected from at least one of N-hydroxymethyl acrylamide, N-hydroxyethyl acrylamide, N-[tris(hydroxymethyl)methyl]acrylamide, N-(2-hydroxypropyl)acrylamide, N-(hydroxymethyl)methacrylamide, N-(hydroxyethyl)methacrylamide, N-[tris(hydroxymethyl)methyl]methacrylamide or N-(2-hydroxypropyl)methacrylamide; the ionic monomer is selected from at least one of sodium acrylate, sodium methacrylate, sodium p-styrene sulfonate or sodium vinyl sulfonate.

3. The visualized radioembolization microsphere according to claim 1, characterized in that: The particle size of the visualized radioembolization microspheres is 100 to 500 μm.

4. The visualized radioembolization microsphere according to claim 1, characterized in that: The suspension time of the visualized radioembolization microspheres in physiological saline is greater than 5 minutes.

5. The visualized radioembolization microsphere according to claim 1, characterized in that: The density of the visualized radioembolization microspheres is less than 1.25 g / cm 3 .

6. The visualized radioembolization microsphere according to any one of claims 1 to 5, characterized in that: The preparation method of the embolic microspheres comprises the following steps: Preparing an aqueous phase: subjecting the ethylene glycol glycidyl ether compound to a cross-linking reaction with an aqueous solution of the N-hydroxyalkyl acrylamide compound, and then adding the ionic monomer and the initiator after the cross-linking to prepare an aqueous phase; Preparing the oil phase: mixing the oil-soluble dispersant and the oil-soluble solvent to form the oil phase; Inverse suspension polymerization reaction: Under certain temperature and stirring conditions, slowly add water phase to the oil phase to form an oil-in-water reverse suspension polymerization system, add a certain amount of catalyst to the reaction system, raise the temperature to a predetermined temperature, and when the reaction is completed, the embolic microspheres with a core-shell structure are obtained.

7. A method for preparing visualized radioembolization microspheres according to any one of claims 1 to 6, characterized in that: The following steps are involved: The embolic microspheres are loaded with barium sulfate through a first ion exchange to obtain visualized embolic microspheres; The visualized embolic microspheres are loaded with a second ion exchange 90 YF3, obtain the visualized radioembolization microspheres.

8. The preparation method according to claim 7, characterized in that: The first ion exchange step comprises: The embolic microspheres are dehydrated and dried, mixed with a soluble barium salt aqueous solution, stirred, and precipitated to obtain a loaded Ba 2+ of microspheres; To the load Ba 2+ A soluble sulfate aqueous solution is added to the microspheres, and after stirring and precipitation, the visualized embolization microspheres loaded with barium sulfate are obtained.

9. The preparation method according to claim 7, characterized in that: The second ion exchange step comprises: The visualized embolization microspheres are dehydrated and dried, mixed with a soluble yttrium salt aqueous solution, stirred, and precipitated to obtain a loaded 90 Y 3+ Visualization of embolic microspheres; To the load 90 Y 3+ A saturated soluble fluoride salt solution was added to the visualized embolization microspheres, and the loaded 90 Visualization of YF3 radioembolization microspheres.

10. Use of the visualized radioembolization microspheres according to any one of claims 1 to 6 in the preparation of a drug for treating solid malignant tumors.